科创成长层首批新注册上市企业来了！禾元生物正式启动发行

Core Points - He Yuan Bio is the first company to initiate its issuance under the new registration system of the Sci-Tech Innovation Board, marking a significant step in the implementation of the "1+6" reform [1][2] - The company has developed an innovative "rice-derived blood" technology, which has received support from the national "Major New Drug Creation" program, and its recombinant human albumin injection (rice) was approved for market entry in July [2] - The issuance plan includes a differentiated lock-up and allocation arrangement for offline investors, with a minimum lock-up ratio of 40% and a ninefold allocation ratio for the highest lock-up tier compared to the lowest [2] Industry Context - The launch of He Yuan Bio's issuance reflects the regulatory body's commitment to enhancing the inclusivity and adaptability of the system for high-quality technology enterprises [2] - The Shanghai Stock Exchange has implemented various measures to promote the "Eight Articles of Sci-Tech Innovation Board" and the "1+6" reform policies, with all supporting rules now in effect [1] - As of now, 5 million investors have opened trading permissions for the new registration system, indicating a growing interest in the Sci-Tech Innovation Board [1]